Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Dizal (Jiangsu) Pharmaceutical Co. Ltd. maintains a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active for this entity. These 2 pending office actions are distributed across 2 distinct examiners and 2 distinct art units, indicating that the company's current prosecution efforts are not concentrated in a single examination silo. This spread suggests that the company is advancing multiple innovations that require specialized review from different units within the Biotechnology & Pharmaceuticals sector.
WILLIS, DOUGLAS M is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner is responsible for 1 of the 2 pending office actions currently recorded. The use of 2 distinct examiners and 2 distinct art units for these actions suggests that the company's applications involve diverse technologies. Managing these pending actions across different units requires a strategy that accounts for the varying examination cultures and timelines present in each of the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| HIRAKIS, SOPHIA P | 1 | 56.1% | +73.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18066275 | PYRAZINE COMPOUNDS AND USES THEREOF | WILLIS, DOUGLAS M | 55d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17885578 | ERBB RECEPTOR INHIBITORS | HIRAKIS, SOPHIA P | 23d overdue |
| 18066275 | PYRAZINE COMPOUNDS AND USES THEREOF | WILLIS, DOUGLAS M | 55d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18066275 | PYRAZINE COMPOUNDS AND USES THEREOF | WILLIS, DOUGLAS M | 1624 | §112Other | Final Rejection | 55d | Pending | Dec 14, 2022 |
| 17885578 | ERBB RECEPTOR INHIBITORS | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | 23d overdue | Pending | Aug 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial